1 motako kannabinoide hartzaile (CB1) astroglialaren adierazpena loki-lobuloko epilepsia ereduan

Abstract

Loki-lobuloko epilepsia (LLE) mundu osoko pertsonen %1-3ri eragiten dien afekzio neurologiko ohikoenetako bat da, eragin izugarria izanik pazienteen bizitzan. Horregatik, epilepsien fisiopatologia argitzea premiazkoa suertatzen da tratamendu antiepileptiko berriak garatu ahal izateko. Ikerketa honetan, CB1 hartzaile astroglialaren espresioan zentratu gara, CB1 astroglialak zitotoxikotasunean duen eginkizunari buruzko emaitza kontraesankorrak baitaude. Ikerketa honen hipotesiaren arabera, hipokanpoko CB1 hartzaile astroglialek funtsezko rola betetzen dute epilepsiaren fisiopatologian. Hemen, CB1 hartzaile astroglialaren hipokanpoko espresioa ikertu dugu azido kainiko LLE animalia-eredu batean.Temporal lobe epilepsy (TLE) is one of the most common neurological conditions affecting 1-3% people worldwide and having a tremendous impact on patients´ life. It is therefore crucial to elucidate the pathophysiology of the epilepsies with the aim of generating novel antiepileptic treatments. In this study, we have focused on the expression of CB1 receptor in astroglia, as there are conflicting results regarding the role of astroglial CB1 receptors in excitotoxicity. The hypothesis in this study is that CB1 receptors localized in astrocytes of the hippocampus play a key role in the pathophysiology of epilepsy. Here, we have investigated the CB1 receptor astroglial expression in the hippocampus of a kainic acid TLE mouse model.